A recent survey commissioned by the Alliance for Aging Research and sponsored by Lundbeck and Otsuka has revealed significant gaps in understanding the agitation experienced by Alzheimer’s patients. The survey included responses from 1,000 U.S. adults and an equal number of unpaid or family caregivers, highlighting a critical area of concern in Alzheimer’s care.
This finding underscores the need for increased awareness and targeted research into the behavioral symptoms of Alzheimer’s, particularly agitation, which can severely impact the quality of life for patients and their families. The involvement of major pharmaceutical companies in this survey indicates a growing recognition of the importance of addressing these non-cognitive symptoms in treatment protocols.
As the pharmaceutical industry continues to innovate, the insights gained from this survey could influence future drug development and care strategies, ultimately leading to improved patient outcomes and a more comprehensive approach to Alzheimer’s disease management.
Open the full market picture for your next decision →
